Blood sample: Blood sample (20mL) for pro-inflammatory cytokines assay
Study summary
Chronic inflammatory rheumatic diseases (CIRD) affect many organ systems. Painful sensations within the joints spine, hand and foot deformities, low quality of life and psychosocial status in patients with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis can lead to the development of anxiety and depression. Prevalences of anxiety increase in patients suffering of CIRD, compared with healthy individuals. Another connection has been identified by the links between depression and systemic inflammation. It is proven that higher plasma levels of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNFa) affect neurotransmitter metabolism, with influence on patients mood. The purpose of EMOTION study is therefore to analyze thymic variation under TNFa therapy, as treatment of CIRDs.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
* Adult patients (≥18 ; ≤ 80)
* Patient with rheumatoid arthritis (RA) according to the ACR 2010 criteria, axial or peripheral spondyloarthritis (SpA) according to ASAS criteria, ankylosing spondylitis (AS) according to the New York criteria or psoriatic arthritis (PsA) according to CASPAR criteria
* Signature of informed consent
* Affiliation to a French social security or receiving such a scheme
Exclusion Criteria:
* Patient having previously received anti-TNFα treatment
* Patient with previously diagnosed depressive or psychiatric pathology and / or receiving anti-depressant treatment
* Subjects with limited legal capacity.
* Subjects judged by the investigator to be unlikely to comply with study procedures
* Subjects with no social security coverage.
* Pregnant women.
* Subjects still in the exclusion period of another study, or according to the national registry of clinical trial participants.
Primary outcome measure(s)
Severity of depressive symptoms — 1 month after initiation of anti-TNFa therapy Score achieved on the validated self-report questionnaire (QIDS SR16) evaluating the severity of depressive symptoms
Trial sites (1)
Facility
City
Region
Status
University Hospital
Besançon
France
Recruiting
More Centre Hospitalier Universitaire de Besancon trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
